#### Supplementary material 1

# ASIA PACIFIC ASSOCIATION OF ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (APAAACI) SURVEY ON DRUG ALLERGY DIAGNOSTIC PROCEDURES & PRACTICES 2020

Thank you for spending some time to fill in this questionnaire. The objective of this is to survey the types of diagnostic procedures and practice parameters being used by APAAACI members for evaluation of drug allergy/hypersensitivity in both adults and children. It is our hope that the results of this survey will facilitate collaboration and education among the different allergy centres, and help develop care guidances that are specific to our region.

Please check al	ll answers that apply.	
Name of Society	ty:	
1 APAAAC	Australasian Society of Clinical Immunology and Allergy (ASCIA) Asthma Allergy and Clinical Immunology Association of Thailand Allergy and Clinical Immunology Society (Singapore) ACIS Allergy and Immunology Society of Sri Lanka Bangladesh Society of Allergy and Immunology Chinese Society of Allergology Hong Kong Institute of Allergy Indian College of Allergy, Asthma and Applied Immunology Indonesian Society of Allergy and Immunology Japanese Society of Allergology (JSA) Korean Academy of Asthma Allergy and Clinical Immunology (KAACI) Malaysian Society of Allergy and Immunology (MSAI) Mongolian Society of Allergy, Asthma and Immunology Taiwan Academy of Allergy, Asthma and Clinical Immunology Individual members	
2 Do the All	llergy Clinics in your country carry out evaluation for drug hypersensitivity/allergy?  Yes No	
hypersens	Dermatology Clinics in your country carry out evaluation for drug Yes sitivity/allergy?  No  No  No  No	
1. DRUG	G ALLERGY	
1.1	EAACI 2019: <u>EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity</u>	
1.2	EAACI 2018: Recognizing the potential of the primary care physician in the diagnosis and management of drug hypersensitivity	
1.3 1.4	ENDA/EAACI 2016: <u>Drug allergy passport and other documentation for patients with drug hypersensitivity – An ENDA/EAACI Drug Allergy Interest Group Position Paper ENDA/EAACI 2016</u> : In vitro tests for Drug Hypersensitivity Reactions. An ENDA/EAACI Drug Allergy Interest Group Position Paper (2016)	
1.5	ICON 2014: International Consensus on Drug Allergy	
1.6	AAAAI 2010: Drug allergy: an updated practice parameter	
1.7	BSACI 2009: BSACI guidelines on the management of drug allergy	

#### 2. ANTIBIOTIC ALLERGY

- 2.1 EAACI 2019: <u>Towards a more precise diagnosis of hypersensitivity to beta-lactams an EAACI position paper</u>
- 2.2 WAO 2013: <u>Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy</u>
- 2.3 EAACI 2009: <u>Update on evaluation of hypersensitivity reactions to betalactams</u>
- 2.4 EAACI 2003: Diagnosis of immediate allergic reactions to beta-lactam antibiotics

#### 3. NSAID HYPERSENSITIVITY

- 3.1 SEAIC 2019: <u>Position Statement of the Spanish Society of Allergology and Clinical Immunology</u> on Provocation Tests with Aspirin/Nonsteroidal anti-inflammatory drugs
- 3.2 EAACI 2013: <u>Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)</u> <u>classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA\*</u>

#### 4. INTRA-OPERATIVE ANAPHYLAXIS/ ANAESTHETIC AGENTS

- 4.1 <u>EAACI 2019: Position paper on the investigation of perioperative immediate hypersensitivity reactions</u>
- 4.2 <u>Spanish Society of Allergology and Clinical Immunology (2018): Practical guidelines for perioperative hypersensitivity reactions</u>
- 4.3 SFAR 2011: Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice
- 4.4 BSACI 2009: <u>BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia</u>

#### 5. RADIOCONTRAST MEDIA

- 5.1 Spanish Society of Allergology and Clinical Immunology 2015: Clinical practice guidelines on the diagnosis and management of hypersensitivity reactions to contrast media
- 5.2 EAACI 2005: Management of hypersensitivity reactions to iodinated contrast media

#### 6. VACCINE ADVERSE REACTIONS

- 6.1 Practice parameter 2017: Administration of influenza vaccines to egg allergic recipients
- 6.2 AAAAI 2012: Adverse reactions to vaccines 2012 parameter update

#### 7. SKIN TESTS

- 7.1 ASCIA 2016: Skin prick testing for the diagnosis of allergic diseases (practitioner's manual)
- 7.2 EAACI 2015: <u>In-vivo Diagnosis of Allergic Diseases Allergen Provocation Tests</u>
- 7.3 EAACI 2013: Skin test concentrations for systemically administered drugs an ENDA/EAACI Drug Allergy Interest Group position paper
- 7.4 Patch testing in non-immediate drug eruptions by Romano A (2008)
- 7.5 AAAAI 2008: Allergy diagnostic testing: an updated practice parameter

#### 8. IN-VITRO TESTS

- 8.1 EAACI 2016: In-vitro tests for drug hypersensitivity reactions
- 8.2 EAACI 2015: <u>The Clinical Utility of Basophil Activation Testing in Diagnosis and Monitoring of Allergic Disease</u>

#### 9. DRUG PROVOCATION TESTS

- 9.1 WAO 2016: Risk and safety requirements for diagnostic and therapeutic procedures in allergology
- 9.2 EAACI/GA<sup>2</sup>LEN guideline 2007: <u>Aspirin provocation tests for diagnosis of aspirin hypersensitivity</u>
- 9.3 EAACI 2003: <u>Drug provocation testing in the diagnosis of drug hypersensitivity reactions:</u> general considerations

#### 10. DESENSITIZATION

- 10.1 EAACI 2013: <u>Desensitization in delayed drug hypersensitivity reactions an EAACI position paper of the Drug Allergy Interest Group</u>
- 10.2 EAACI 2010: General considerations on rapid desensitization for drug hypersensitivity a consensus statement

#### 11. PHARMACOGENOMIC TESTING

Clinical Pharmacogenomics Implementation Consortium (CPIC) Guidelines & Publications

#### 12. STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS

12.1 British Association of Dermatologists Guidelines 2016

#### 13. MASTOCYTOSIS AND MAST CELL ACTIVATION SYNDROMES

- 13.1 <u>EAACI 2015: Drug hypersensitivity in clonal mast cell disorders</u>
- 13.2 Mastocytosis and allergic diseases (2015)

#### 14. PAEDIATRIC DRUG ALLERGY

9 From where do you obtain your skin test

- EAACI 2019: <u>Diagnosis and management of drug induced anaphylaxis in children: an EAACI position paper</u>
- 14.2 <u>EAACI 2018: Diagnosis and management of hypersensitivity reactions to NSAIDs in children</u> and adolescents
- 14.3 NICE 2014: Diagnosis and management of drug allergy in adults, children and young people
- 14.4 Royal College of Paediatrics and Child Health (RCPCH) 2012: <u>Allergy Care pathway for</u> Children Drug Allergy

5	Are there adult drug allergy centres/clinics in	Yes: please specify the number:	
	your country?	No	
6	Are there paediatric drug allergy	Yes: please specify the number:	
	centres/clinics in your country?	No	
7	Which of the following tests for drug	Skin prick and intradermal test → go to section (A)	
	allergy/hypersensitivity are available in your	Specific IgE in-vitro tests → go to section (B)	
	country?	Other tests for immediate reactions $\rightarrow$ go to section (C)	
		Lymphocyte transformation test $\rightarrow$ go to section (D)	
		Patch testing $\rightarrow$ go to section (E)	
		Pharmacogenomic tests $\rightarrow$ go to section (F)	
		Drug provocation tests $\rightarrow$ go to section (G)	
	(A) SKIN TESTING		
8	Do you have access to penicillin skin test	Yes	
	reagents?	No	

# reagent for benzylpenicilloyl polylysine (PPL)? Others – specify: IO From where do you obtain your skin test reagent for minor determinant mix (MDM)? Others – specify: In-house Diater ® Others – specify: II Which drugs are commonly skin tested in your country? Penicillins Cephalosporins

In-house

	Carbapenems	
	Non-beta lactam antibiotics	
	General anaesthetic agents	
	Local anaesthetic agents	
	Radiocontrast media (RCM)	
	NSAIDs	<del>                                     </del>
	Others – specify: Corticosteroids, Insulins	<del>   </del>
12 Who prepares the drugs for skin testing?	Allergist	
	Dermatologist	
	Pharmacist	
	Nurse clinician/specialist	
	Others – specify:	
(B) SPECIFIC IgE IN-VITRO TESTS		
13 Are in-house or commercial assays available	Commercial	
for these tests?	In-house	
101 41303 13000	Both	
	Neither	
The Transfer of the Control of the C		
Which commercial tests are available in your	CAP-FEIA (Phadia ImmunoCAP®)	
country?	RAST (Radioallergosorbent test®)	
	Euroimmune Allercoat 6 ELISA	
	FLOW-CAST (Buhlmann Labs®)	
	FLOW-2-CAST (Buhlmann Labs®)	
	CAST-ELISA (Buhlmann Labs®)	
	Others – specify:	
15 Which drugs are commonly tested using these	Alfa-gal	
in-vitro methods?	Ampicilloyl	
	Amoxicilloyl	
	Cefaclor	
	Cephalosporins	
	Chlorhexidine	<del>       </del>
	Chymopapain Gelatin	<del>     </del>
		<del>       </del>
	General anaesthetic agents	
	Insulin porcine, human, bovine	
	Morphine	
	NSAIDs	
	Penicilloyl G	
	Penicilloyl V	
	Pholcodine	
	Protamine	
	Suxamethonium	
	Tetanus toxoid	
	Others – specify:	
	1 -	

## (C) OTHER TESTS FOR IMMEDIATE REACTIONS

16 Is serum total tryptase available in your	Yes	
country?	No	
17 Is the basophil activation test (BAT) available	Yes	
in your country?	No	
(D) I VMDHO CVET TO ANGEODMATI	ON TRECTO (LTT)	
(D) LYMPHOCYTE TRANSFORMATI	ON TESTS (LTT)	
18 Is LTT used in the clinical or research setting?	Clinical	
	Research	
	Both clinical and research	
Where are these tests done?	In-house	
	Sent to another facility in the same region/country	
	Sent to another facility out of the region/country	
20 What drugs are commonly tested using LTT in	Antibiotics (beta-lactams)	
your country?	Antibiotics (non-beta lactams)	
	Anti-epileptics	
	ACE inhibitors	
	Anti-tuberculous drugs	
	Diuretics	
	NSAIDs & selective COX-2 inhibitors	
	Pyrazolones	
	Local anaesthetic agents	
	HMG-CoA reductase inhibitors	
	Opioids	<del>     </del>
	Neuromuscular blockers	<del>     </del>
	Contact allergens Others - specify:	<del>                                     </del>
21 For what types of delayed reactions are LTT	Acute generalized exanthematous pustolosis (AGEP)	
commonly used for diagnosis?	Blood dyscracias (cytopaenias)	
	Drug induced hypersensitivity syndrome (DiHS)	<del>     </del>
	Fixed drug eruption (FDE)	<del>     </del>
	Hepatitis Immunobullous eruptions	<del>     </del>
	Interstitial nephritis	
	Maculopapular exanthems (MPE)	<del>     </del>
	Stevens Johnson syndrome	<del>     </del>
	Toxic epidermal necrolysis	
	Vasculitis	H
	Others – specify:	
		<u> </u>
(E) PATCH TESTS		
22 Is this used in the clinical or research setting?	Clinical	
	Research	
	Both clinical and research	
23 What formulation of the drug is used for	Pure substance	
testing?	Commercialized form of the drug	IT
-	Others – specify:	

24	What dilutions of the drug are used	0.1%	
		1%	
		5%	
		10% and 30%	
25	What vehicle is used?	Petrolatum	
		Water	
		Alcohol	
26	How do you obtain the drugs for patch testing?	In-house	П
	g.	Chemotechnique®	Ħ
		Commercial - specify:	Ħ
		Others - specify:	Ħ
27	Which of the following are also tested?	Preservative	
21	which of the following are also tested:	Colouring	H
		Excipient	H
		None of the above	H
20	Will be described by the second		Н
28	When is the patch test reading done?	20 minutes	H
		48 h (Day 2)	H
		96 h (Day 4)	H
		Day 7 if Day 2,4 negative	Щ
29	Is photo patch testing done for photoallergens?	Yes	Щ.
		No	Щ
30	What drugs have you used for patch testing?	Antibiotics (beta-lactams)	
		Antibiotics (non-beta lactams)	
		Anti-epileptics	Ш
		Anti-tuberculous drugs	
		Aciclovir, valaciclovir	
		Corticosteroids	
		NSAIDs & selective COX-2 inhibitors	Ш
		Cotrimoxazole	Ш
		Diltiazem	Ш
		Hydroxyzine	Ш
		Heparin derivatives	Ш
		Pseudoephedrine	Ш
		Radiocontrast media	Щ
		Statins	Щ
		Tetrazepam	Щ
		Others - specify:	Ш
31	For what types of delayed reactions have you	Acute generalized exanthematous pustolosis (AGEP)	
	used patch testing to help in diagnosis?	Drug induced hypersensitivity syndrome (DiHS)	
		Drug induced lupus erythematosus (DILS)	
		Fixed drug eruption (FDE)	
		Immunobullous eruptions	
		Maculopapular exanthems (MPE)	
		Stevens Johnson syndrome	
		Symmetrical drug-related intertriginous and flexural exanthema	
		(SDRIFE)	<u> </u>
		Toxic epidermal necrolysis	닏
		Vasculitis	
		Others – specify:	oxdot

### (F) PHARMACOGENOMIC TESTS

32	Which tests are <b>mandatory</b> in your country before prescribing?	HLA-B*5701 (Abacavir) HLA-B*5801 (Allopurinol) HLA-B*1502 (Carbamazepine) Others – specify:	
33	Which tests are <b>recommended</b> in your country before prescribing?	HLA-B*5701 (Abacavir) HLA-B*5801 (Allopurinol) HLA-B*1502 (Carbamazepine) Others – specify:	
	(G) DRUG PROVOCATION TESTS		
34	What are the main indications for drug provocat	tion tests in your centre/country?	
	Exclude cross-reactivity of related drugs in prov	y/non-specific symptoms) n-related drugs in proven hypersensitivity (e.g. beta-lactams) yen hypersensitivity (e.g. cephalosporin in a penicillin allergic) negative, non-conclusive or non- available allergological tests	
35	Who prepares the drug used for provocation testing?	Pharmacist Nurse clinician Doctor (IV/SC) Others – specify:	
36	What are the types of provocation tests used?	Open challenge Single blind placebo control Double blind placebo control Others – specify:	
37	What are the common routes of administration used?	Oral (tablet) Oral (capsule) Oral (syrup) Intramuscular Subcutaneous Intravenous Others – specify:	
38	What are the common routes of administration for aspirin provocation tests ?	Oral aspirin challenge Bronchial (inhalation) l-lysine-aspirin (l-ASA) challenge Nasal l-ASA challenge	

# **DESENSITIZATION**

39 What are the common drugs for which	Betalactam antibiotics	
desensitizations are done?	Non-betalactam antibiotics –specify:	
	Chemotherapeutic agents	
	Monoclonal antibodies	
	High-dose aspirin (chronic rhinosinusitis+/-nasal polyposis)	
	Low-dose aspirin (coronary artery disease)	
	Others – specify:	
40 Which are the common modes of	Rapid	
desensitization?	Slow	
	Both rapid and slow	
41 Where are these commonly done?	Inpatient general wards	
	Inpatient high dependency/ intensive care units	
	Outpatient day ward	
	Outpatient clinic	
	Others: specify:	

Thank you for completing this survey.

Drug Allergy Committee, APAAACI